دورية أكاديمية
Cutaneous adverse drug reactions.
| العنوان: | Cutaneous adverse drug reactions. |
|---|---|
| المؤلفون: | Bettuzzi T; Service de dermatologie, hôpital Henri-Mondor, AP-HP, 94000 Créteil, France; EpiDermE, université Paris Est Créteil Val-de-Marne, 94000 Créteil, France., Sanchez-Pena P; Service de pharmacologie médicale, centre régional de pharmacovigilance de Bordeaux, CHU de Bordeaux, 33000 Bordeaux, France; Groupe FISARD de la Société française de dermatologie, France., Lebrun-Vignes B; EpiDermE, université Paris Est Créteil Val-de-Marne, 94000 Créteil, France; Groupe FISARD de la Société française de dermatologie, France; Service de pharmacologie médicale, centre régional de pharmacovigilance Pitié-Saint-Antoine, groupe hospitalier AP-HP-Sorbonne université, 75013 Paris, France. Electronic address: benedicte.lebrun-vignes@aphp.fr. |
| المصدر: | Therapie [Therapie] 2024 Mar-Apr; Vol. 79 (2), pp. 239-270. Date of Electronic Publication: 2023 Oct 31. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Masson Country of Publication: France NLM ID: 0420544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1958-5578 (Electronic) Linking ISSN: 00405957 NLM ISO Abbreviation: Therapie Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2016- : Paris : Elsevier Masson Original Publication: Paris : Doin |
| مواضيع طبية MeSH: | Stevens-Johnson Syndrome*/epidemiology , Stevens-Johnson Syndrome*/etiology , Stevens-Johnson Syndrome*/diagnosis , Acute Generalized Exanthematous Pustulosis*/diagnosis , Acute Generalized Exanthematous Pustulosis*/epidemiology , Acute Generalized Exanthematous Pustulosis*/etiology, Humans ; Skin ; Anti-Bacterial Agents/adverse effects ; Anti-Inflammatory Agents, Non-Steroidal/adverse effects |
| مستخلص: | Cutaneous adverse drug reactions (ADRs) represent a heterogeneous field including various clinical patterns without specific features suggesting drug causality. Maculopapular exanthema and urticaria are the most common types of cutaneous ADR. Serious cutaneous ADRs, which may cause permanent sequelae or have fatal outcome, may represent 2% of all cutaneous ADR and must be quickly identified to guide their management. These serious reactions include bullous manifestations (epidermal necrolysis i.e. Stevens-Johnson syndrome and toxic epidermal necrolysis), drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalized exanthematous pustulosis (AGEP). Some risk factors for developing cutaneous ADRs have been identified, including immunosuppression, autoimmunity or genetic variants. All drugs can cause cutaneous ADRs, the most commonly implicated being antibiotics (especially aminopenicillins and sulfonamides), anticonvulsants, allopurinol, antineoplastic drugs, non-steroidal anti-inflammatory drugs and iodinated contrast media. Pathophysiology is related to immediate or delayed "idiosyncratic" immunologic mechanisms, i.e., usually not related to dose, and pharmacologic/toxic mechanisms, commonly dose-dependent and/or time-dependent. If an immuno-allergic mechanism is suspected, allergological explorations (including epicutaneous patch testing and/or intradermal test) are often possible to clarify drug causality, however these have a variable sensitivity according to the drug and to the ADR type. No in vivo or in vitro test can consistently confirm the drug causality. To determine the origin of a rash, a logical approach based on clinical characteristics, chronologic factors and elimination of differential diagnosis (especially infectious etiologies) is required, completed with a literature search. Reporting to pharmacovigilance system is therefore essential both to analyze drug causality at individual level, and to contribute to knowledge of the drug at population level, especially for serious cutaneous ADRs or in cases involving newly marketed drugs. (Copyright © 2023 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Cutaneous adverse drug reactions; Pharmacovigilance |
| المشرفين على المادة: | 0 (Anti-Bacterial Agents) 0 (Anti-Inflammatory Agents, Non-Steroidal) |
| تواريخ الأحداث: | Date Created: 20231118 Date Completed: 20240401 Latest Revision: 20240401 |
| رمز التحديث: | 20240401 |
| DOI: | 10.1016/j.therap.2023.09.011 |
| PMID: | 37980248 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1958-5578 |
|---|---|
| DOI: | 10.1016/j.therap.2023.09.011 |